Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$110.38 USD

110.38
55,245

-3.89 (-3.40%)

Updated Sep 6, 2024 12:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand

DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.

    Omnicell Continues to Pursue Buyouts, Costs on the Rise

    Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.

      AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology

      AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.

        Cardiovascular Systems Portfolio Strong, Competition Rife

        Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.

          Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel

          Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.

            DENTSPLY Launches Azento, Improves Digital Implant Workflow

            DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.

              Here's Why You Should Invest in Penumbra (PEN) Stock Now

              The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.

                Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio

                IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.

                  Nabaparna Bhattacharya headshot

                  Allscripts' Sunrise Abstracting Selected by Wyckoff Heights

                  Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.

                    Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT

                    Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.

                      Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio

                      A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.

                        Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio

                        Stryker (SYK) on an acquisition spree; latest buyout likely to aid its array of surgical instruments.

                          Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?

                          Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.

                            Here's Why You Should Hold On to DaVita (DVA) Stock Now

                            Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.

                              Integra Lifesciences Picked for Healogics iSupply Program

                              Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.

                                Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals

                                Varian's (VAR) advanced cancer care solution prospects bright in the global market.

                                  Here's Why You Should Invest in Surmodics (SRDX) Stock Now

                                  Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.

                                    IDEXX Gains Ground on Solid CAG Business Amid Forex Woes

                                    IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.

                                      Here's Why You Should Hold On to Quest Diagnostics (DGX) Now

                                      Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.

                                        Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout

                                        Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.

                                          Penumbra Launches Reperfusion Catheters, Boosts Neuro Unit

                                          Penumbra (PEN) adopts initiatives to boost the highest revenue generating Neuro business.

                                            Genomic Health Prostate Cancer Business Solid, Cost Woes Stay

                                            Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.

                                              Here's Why You Should Invest in athenahealth (ATHN) Now

                                              Focus on cloud-based services and a lifted guidance for 2018 make athenahealth (ATHN) an attractive pick.

                                                Varian's (VAR) ProBeam System Gets Picked by Delray Medical

                                                Varian Medical's (VAR) coveted ProBeam platform sees a slew of developments; market prospects solid.

                                                  Here's Why You Should Hold on to Abiomed (ABMD) for Now

                                                  Abiomed's (ABMD) margin continues to remain pressed; an upbeat view for fiscal 2019 encourages.